Induced pluripotent stem cells and regenerative medicine

Journal of Clinical Gerontology and Geriatrics

Volumn 2, Issue 1, 2011, Pages 1-6

  Chen, Yuh Chi ^a,b   Tsai, Kung Lin ^a,b   Hung, Chia Wei ^b,c   Ding, Dah Ching ^d   Chen, Lih Hsin ^b   Chang, Yuh Lih ^a,b   Chen, Liang Kung ^a,b   Chiou, Shih Hwa ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Embryonic stem cell; Induced pluripotent stem cell; Regenerative medicine; Stem cells

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ACUTE LUNG INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SURGERY; CELL DIFFERENTIATION; CHINESE MEDICINE; DEGENERATIVE DISEASE; DEPRESSION; DRUG RESEARCH; DYSKINESIA; EMBRYONIC STEM CELL; FIBROBLAST; GENE EXPRESSION; HUMAN; IMMUNOPATHOLOGY; INFECTION; KINESIOTHERAPY; LIVER DISEASE; NEURAL STEM CELL; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATIVE STRESS; PARKINSON DISEASE; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; STEM CELL TRANSPLANTATION; STROKE; TERATOMA; TRANSLATIONAL RESEARCH;

EID: 79953893337     PISSN: 22108335     EISSN: 22108343     Source Type: Journal    
DOI: 10.1016/j.jcgg.2010.12.003     Document Type: Review

References (96)

1. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res 2009;81:482-90.
2. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981;292:154-6. (Pubitemid 11050741)
3. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 1981;78:7634-8. (Pubitemid 12186197)
4. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-7. (Pubitemid 28516247)
5. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76. (Pubitemid 44233629)
6. Hanna J, Carey BW, Jaenisch R. Reprogramming of somatic cell identity. Cold Spring Harb Symp Quant Biol 2008;73:147-55.
7. Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008;3:595-605.
8. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136:964-77.
9. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hamalainen R, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458:766-70.
10. Yusa K, Rad R, Takeda J, Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods 2009;6:363-9.
11. Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009;4:16-9.
12. Liao J, Cui C, Chen S, Ren J, Chen J, Gao Y, et al. Generation of induced pluripotent stem cell lines from adult rat cells. Cell Stem Cell 2009;4:11-5.
13. Liu H, Zhu F, Yong J, Zhang P, Hou P, Li H, et al. Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell 2008;3:587-90.
14. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72. (Pubitemid 350138099)
15. Sun N, Longaker MT, Wu JC. Human iPS cell-based therapy: considerations before clinical applications. Cell Cycle 2010;9:880-5.
16. Feng B, Ng JH, Heng JC, Ng HH. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009;4:301-12.
17. Colman A, Dreesen O. Induced pluripotent stem cells and the stability of the differentiated state. EMBO Rep 2009;10:714-21.
18. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, et al. Patientspecific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363:1397-409.
19. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-7. (Pubitemid 47080336)
20. Wernig M, Meissner A, Cassady JP, Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. Cell Stem Cell 2008;2:10-2.
21. Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 2007;25:1177-81. (Pubitemid 47538112)
22. Nakagawa Masato, Koyanagi Michiyo, Tanabe Koji, Takahashi Kazutoshi, Ichisaka Tomoko, Aoi Takashi, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nature Biotechnology 2008;26:101-6.
23. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008;322:945-9.
24. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008;322:949-53.
25. Somers A, Jean JC, Sommer CA, Omari A, Ford CC, Mills JA, et al. Generation of transgene-free lung disease-specifichumaninduced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010;28:1728-40.
26. Carey BW, Markoulaki S, Hanna J, Saha K, Gao Q, Mitalipova M, et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci USA 2009;106:157-62.
27. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009;458:771-5.
28. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381-4.
29. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, Lau F, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-30.
30. Sauer H, Rahimi G, Hescheler J, Wartenberg M. Role of reactive oxygen species and phosphatidylinositol 3-kinase in cardiomyocyte differentiation of embryonic stem cells. FEBS Lett 2000;476:218-23. (Pubitemid 30410821)
31. Schmelter M, Ateghang B, Helmig S, Wartenberg M, Sauer H. Embryonic stem cells utilize reactive oxygen species as transducers of mechanical strain-induced cardiovascular differentiation. FASEB J 2006;20:1182-4.
32. Papaharalambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 2007;17:48-54. (Pubitemid 46205327)
33. Armstrong L, Tilgner K, Saretzki G, Atkinson SP, Stojkovic M, Moreno R, et al. Human induced pluripotent stem cell lines show stress defense mechanisms and mitochondrial regulation similar to those of human embryonic stem cells. Stem Cells 2010;28:661-73.
34. Crespo FL, Sobrado VR, Gomez L, Cervera AM, McCreath KJ. Mitochondrial reactive oxygen species mediate cardiomyocyte formation from embryonic stem cells in high glucose. Stem Cells 2010;28:1132-42.
35. Ji AR, Ku SY, Cho MS, Kim YY, Kim YJ, Oh SK, et al. Reactive oxygen species enhance differentiation of human embryonic stem cells into mesendodermal lineage. Exp Mol Med 2010;42:175-86.
36. Varum S, Momcilovic O, Castro C, Ben-Yehudah A, Ramalho-Santos J, Navara CS. Enhancement of human embryonic stem cell pluripotency through inhibition of the mitochondrial respiratory chain. Stem Cell Res 2009;3:142-56.
37. Jewett SL, Rocklin AM, Ghanevati M, Abel JM, Marach JA. A new look at a timeworn system: oxidation of CuZn-SOD by H2O2. Free Radic Biol Med 1999;26:905-18. (Pubitemid 29198363)
38. Chen CT, Shih YR, Kuo TK, Lee OK, Wei YH. Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. Stem Cells 2008;26:960-8.
39. Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat Med 2004;(10 Suppl): S42-50.
40. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783-93. (Pubitemid 38698383)
41. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt. 5):2283-301.
42. Lindvall O, Hagell P. Clinical observations after neural transplantation in Parkinson's disease. Prog Brain Res 2000;127:299-320. (Pubitemid 35461264)
43. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-24.
44. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-14. (Pubitemid 37072046)
45. Hagell P, Piccini P, Bjorklund A, Brundin P, Rehncrona S, Widner H, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002;5:627-8. (Pubitemid 34742975)
46. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-9. (Pubitemid 32204988)
47. Hedlund E, Perlmann T. Neuronal cell replacement in Parkinson's disease. J Intern Med 2009;266:358-71.
48. Yang D, Zhang ZJ, Oldenburg M, Ayala M, Zhang SC. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 2008;26:55-63.
49. Glavaski-Joksimovic A, Virag T, Chang QA, West NC, Mangatu TA, McGrogan MP, et al. Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors. Cell Transplant 2009;18:801-14.
50. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol 2009;8:491-500.
51. Takahashi K, Yasuhara T, Shingo T, Muraoka K, Kameda M, Takeuchi A, et al. Embryonic neural stem cells transplanted in middle cerebral artery occlusion model of rats demonstrated potent therapeutic effects, compared to adult neural stem cells. Brain Res 2008;1234:172-82.
52. Yanagisawa D, Qi M, Kim DH, Kitamura Y, Inden M, Tsuchiya D, et al. Improvement of focal ischemia-induced rat dopaminergic dysfunction by striatal transplantation of mouse embryonic stem cells. Neurosci Lett 2006;407:74-9. (Pubitemid 44345014)
53. Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, Soldner F, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 2008;105:5856-61. (Pubitemid 351758462)
54. Chen SJ, Chang CM, Tsai SK, Chang YL, Chou SJ, Huang SS, et al. Functional improvement of focal cerebral ischemia injury by subdural transplantation of induced pluripotent stem cells with fibrin glue. Stem Cells Dev 2010;19:1757-67.
55. Erdo F, Buhrle C, Blunk J, Hoehn M, Xia Y, Fleischmann B, et al. Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. J Cereb Blood Flow Metab 2003;23:780-5. (Pubitemid 36818686)
56. Brederlau A, Correia AS, Anisimov SV, Elmi M, Paul G, Roybon L, et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 2006;24:1433-40. (Pubitemid 44464659)
57. Chung S, Shin BS, Hedlund E, Pruszak J, Ferree A, Kang UJ, et al. Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. J Neurochem 2006;97:1467-80. (Pubitemid 43725585)
58. Tabar V, Panagiotakos G, Greenberg ED, Chan BK, Sadelain M, Gutin PH, et al. Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. Nat Biotechnol 2005;23:601-6. (Pubitemid 41724899)
59. Kao CL, Tai LK, Chiou SH, Chen YJ, Lee KH, Chou SJ, et al. Resveratrol promotes osteogenic differentiation and protects against dexamethasone damage in murine induced pluripotent stem cells. Stem Cells Dev 2010;19: 247-58.
60. Hung CW, Liou YJ, Lu SW, Tseng LM, Kao CL, Chen SJ, et al. Stem cell-based neuroprotective and neurorestorative strategies. Int J Mol Sci 2010;11:2039-55.
61. Christie JD, Edwards LB, Aurora P, Dobbels F, Kirk R, Rahmel AO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation reporte2008. J Heart Lung Transplant 2008;27:957-69.
62. Augoustides JG, Riha H. Recent progress in heart failure treatment and heart transplantation. J Cardiothorac Vasc Anesth 2009;23:738-48.
63. Doetschman TC, Eistetter H, Katz M, Schmidt W, Kemler R. The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol 1985;87:27-45. (Pubitemid 15029925)
64. Iacobas I, Vats A, Hirschi KK. Vascular potential of human pluripotent stem cells. Arterioscler Thromb Vasc Biol 2010;30:1110-7.
65. Xie CQ, Huang H, Wei S, Song LS, Zhang J, Ritchie RP, et al. A comparison of murine smooth muscle cells generated from embryonic versus induced pluripotent stem cells. Stem Cells Dev 2009;18:741-8.
66. Kofidis T, de Bruin JL, Hoyt G, Ho Y, Tanaka M, Yamane T, et al. Myocardial restoration with embryonic stem cell bioartificial tissue transplantation. J Heart Lung Transplant 2005;24:737-44. (Pubitemid 40798258)
67. Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007;25:1015-24. (Pubitemid 47517637)
68. Li Z, Wu JC, Sheikh AY, Kraft D, Cao F, Xie X, et al. Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation 2007;116(11 Suppl):I46-54.
69. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49. (Pubitemid 30408719)
70. Chollet-Martin S, Jourdain B, Gibert C, Elbim C, Chastre J, Gougerot- Pocidalo MA. Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS. Am J Respir Crit Care Med 1996;154(3 Pt 1):594-601. (Pubitemid 26327278)
71. Goodman RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, Maunder RJ, et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;154(3 Pt 1):602-11. (Pubitemid 26327279)
72. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin- 1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992;145:1016-22.
73. Abraham E, Carmody A, Shenkar R, Arcaroli J. Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 2000;279:L1137-1145.
74. Parsey MV, Tuder RM, Abraham E. Neutrophils are major contributors to intraparenchymal lung IL-1 beta expression after hemorrhage and endotoxemia. J Immunol 1998;160:1007-13. (Pubitemid 28049347)
75. Shenkar R, Abraham E. Mechanisms of lung neutrophil activation after hemorrhage or endotoxemia: roles of reactive oxygen intermediates, NF-kappa B, and cyclic AMP response element binding protein. J Immunol 1999;163:954-62. (Pubitemid 29328107)
76. Xing Z, Jordana M, Kirpalani H, Driscoll KE, Schall TJ, Gauldie J. Cytokine expression by neutrophils and macrophages in vivo: endotoxin induces tumor necrosis factor-alpha, macrophage inflammatory protein-2, interleukin-1 beta, and interleukin-6 but not RANTES or transforming growth factor-beta 1 mRNA expression in acute lung inflammation. Am J Respir Cell Mol Biol 1994;10:148-53.
77. Foo SY, Nolan GP. NF-kappaB to the rescue: RELs, apoptosis and cellular transformation. Trends Genet 1999;15:229-35. (Pubitemid 29278676)
78. Treml B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, et al. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit Care Med 2010;38:596-601.
79. Wang D, Morales JE, Calame DG, Alcorn JL, Wetsel RA. Transplantation of human embryonic stem cell-derived alveolar epithelial type II cells abrogates acute lung injury in mice. Mol Ther 2010;18:625-34.
80. Pauluhn J. Comparative assessment of early acute lung injury in mice and rats exposed to 1,6-hexamethylene diisocyanate-polyisocyanate aerosols. Toxicology 2008;247:33-45.
81. Kawashita Y, Guha C, Yamanouchi K, Ito Y, Kamohara Y, Kanematsu T. Liver repopulation: a new concept of hepatocyte transplantation. Surg Today 2005;35:705-10. (Pubitemid 41191396)
82. Horslen SP, Fox IJ. Hepatocyte transplantation. Transplantation 2004;77:1481-6. (Pubitemid 38703025)
83. Fox IJ, Roy-Chowdhury J. Hepatocyte transplantation. J Hepatol 2004;40:878-86. (Pubitemid 38670119)
84. Ito M, Nagata H, Miyakawa S, Fox IJ. Review of hepatocyte transplantation. J Hepatobiliary Pancreat Surg 2009;16:97-100.
85. Weber A, Groyer-Picard MT, Franco D, Dagher I. Hepatocyte transplantation in animal models. Liver Transpl 2009;15:7-14.
86. Puppi J, Dhawan A. Human hepatocyte transplantation overview. Methods Mol Biol 2009;481:1-16.
87. Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001;120:749-62. (Pubitemid 32171644)
88. Lee LA. Advances in hepatocyte transplantation: a myth becomes reality. J Clin Invest 2001;108:367-9. (Pubitemid 32730782)
89. Ott M, Schmidt HH, Cichon G, Manns MP. Emerging therapies in hepatology: liver-directed gene transfer and hepatocyte transplantation. Cells Tissues Organs 2000;167:81-7.
90. Kakinuma S, Nakauchi H, Watanabe M. Hepatic stem/progenitor cells and stem-cell transplantation for the treatment of liver disease. J Gastroenterol 2009;44:167-72.
91. Yoshimi A, Nannya Y, Ueda K, Asano D, Yamamoto G, Kumano K, et al. Successful hematopoietic stem cell transplantation from an HLA-identical sibling in a patient with aplastic anemia after HLA-haploidentical living-related liver transplantation for fulminant hepatitis. Biol Blood Marrow Transplant 2009;15:389-90.
92. Navarro-Alvarez N, Soto-Gutierrez A, Kobayashi N. Stem cell research and therapy for liver disease. Curr Stem Cell Res Ther 2009;4:141-6.
93. Kuo TK, Hung SP, Chuang CH, Chen CT, Shih YR, Fang SC, et al. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 2008;134:2111-21. 2121 e1-e3.
94. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, et al. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 2010;51:297-305.
95. Espejel S, Roll GR, McLaughlin KJ, Lee AY, Zhang JY, Laird DJ, et al. Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J Clin Invest 2010;120:3120-6.
96. Gurdon JB, Melton DA. Nuclear reprogramming in cells. Science 2008;322:1811-5.